toxylact: a07aa antibiotics

The first professional lActological database in the word


This monograph summarizes lactation‑related toxicology for medicines classified in ATC subgroup A07AA “Antibiotics” within intestinal antiinfectives, focusing on maternal use during breastfeeding and potential effects in breastfed infants.atcddd.fhi+2

Subgroup definition and main agents

A07AA is the antibiotics subgroup of A07A (intestinal antiinfectives) and includes orally administered formulations of vancomycin and colistin used in enterocolitis, together with several locally acting intestinal antibiotics and antifungals.atcddd.fhi+2
Representative agents listed under A07AA include neomycin, nystatin, natamycin, streptomycin, polymyxin B, paromomycin and amphotericin B, as well as neomycin‑containing combinations classified under A07AA51.atcddd.fhi+2

Pharmacological characteristics relevant to lactation

Many A07AA antibiotics are formulated for local action in the intestinal lumen with poor systemic absorption when given orally, which tends to limit maternal plasma levels and subsequent passage into breast milk.atcddd.fhi+2
However, systemic absorption can vary with dose, treatment duration and intestinal mucosal integrity, and some molecules (e.g. aminoglycosides or polymyxins) may reach measurable systemic concentrations, so infant exposure cannot be assumed negligible in all situations.atcddd.fhi+2

Breast milk transfer and infant exposure

General lactation pharmacology principles indicate that medicines with low oral bioavailability, high protein binding and short half‑life usually produce low relative infant doses in breastfeeding.medsafe+1
For orally administered vancomycin and colistin, systemic absorption is typically limited in adults, so breast‑milk levels are expected to be low, but specific lactation pharmacokinetic data remain insufficient and benefit–risk assessment is required.atcddd.fhi+2

Potential adverse effects in breastfed infants

The main potential infant adverse effects relate to alterations of intestinal microbiota, with possible diarrhea, candidiasis or, rarely, antibiotic‑associated colitis following maternal A07AA therapy.mayoclinic+1
Additional theoretical risks include selection of resistant organisms, hypersensitivity reactions, and, with some aminoglycosides or polymyxins if significant systemic transfer occurred, ototoxic or nephrotoxic effects, particularly in vulnerable neonates, although documented cases via breast milk are rare.atcddd.fhi+2

Maternal benefits and clinical indications

A07AA antibiotics are indicated for treatment of enterocolitis and intestinal infections, including Clostridioides difficile‑associated diarrhea and staphylococcal enterocolitis, where effective local therapy can be crucial for maternal recovery.pubmed.ncbi.nlm.nih+2
Successful management of these infections supports maternal hydration, nutrition and overall health, which in turn facilitates continuation of breastfeeding and reduces the need for more disruptive systemic regimens.mayoclinic+2

Use during breastfeeding: practical recommendations

Most expert resources state that many antibiotics are compatible with breastfeeding, and therapy should not routinely require cessation of lactation, though drug‑specific data should guide decisions.medsafe+2
For A07AA agents, short‑course treatment at the lowest effective dose, preference for locally acting medicines with poor systemic absorption, and routine infant monitoring are reasonable approaches in healthy term infants.atcddd.fhi+2

Higher‑risk situations and precautions

Premature infants, neonates and those with serious comorbidities (e.g. severe jaundice, renal disease or gastrointestinal pathology) may be more susceptible to microbiota disturbances or drug toxicity and require a more conservative approach.aap+2
In these situations, clinicians should evaluate alternative therapies, consider timing feeds relative to dosing, and seek specialist lactation advice when using A07AA antibiotics.mayoclinic+2

Monitoring and counselling of breastfeeding dyads

During maternal treatment with A07AA medicines, caregivers should be counselled to monitor infants for changes in stool pattern, oral or diaper candidiasis, unusual irritability or lethargy, poor feeding or signs of allergic reaction.medsafe+2
Clear documentation of maternal therapy, discussion of expected benefits and risks, and ready access to medical review if infant symptoms occur all contribute to the safe use of intestinal antibiotics in breastfeeding women.mayoclinic+2

Evidence gaps and research needs

For many A07AA substances, dedicated lactation pharmacokinetic studies and prospective infant outcome data are limited, so current recommendations rely heavily on general antibiotic safety evidence and theoretical considerations.medsafe+2
Further research measuring breast‑milk concentrations, relative infant dose and long‑term microbiome effects would improve the precision of lactation risk assessment for oral intestinal antibiotics.mayoclinic+1


Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.